Torsten Mummenbrauer, CEO Exevir Bio:
"It has been great to partner early on with VIVES fund. VIVES fund helped us to finance the company, challenged us in our thinking to push us further in our...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
Gael Rouvroy, CEO intoPIX :
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Issam Doghri, professor at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Philippe Mengal, past CEO Greenwatt :
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Chris Buyse, Co founder and Managing Partner of Fund+ :
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Eric de La Fortelle, Venture Partner at Seventure Partners :
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...